Inventiva Unveils New Data on Lanifibranor’s Mechanism at AASLD 2026…

Event summary

Inventiva will present three scientific abstracts at AASLD The Liver Meeting® 2026, held November 5-9, 2026 in Denver.
Preclinical and Phase 2b data show lanifibranor improves liver sinusoidal endothelial cell alterations across MASH stages.
Analysis of plasma cell-free DNA (cfDNA) reveals coordinated epigenetic changes across the PPAR family in MASLD patients.
Lanifibranor is in Phase 3 NATiV3 trial for MASH with topline results expected Q4 2026.

The big picture

Inventiva’s presentation at AASLD 2026 underscores the growing focus on multi-target therapies for MASH, a condition with significant unmet medical need. The company’s balanced pan-PPAR approach positions it as a key player in the competitive landscape of liver disease treatments, with potential implications for future regulatory and commercial strategies.

What we're watching

Clinical Trial Outcomes: Whether the Phase 3 NATiV3 trial results will meet regulatory benchmarks for MASH treatment.
Regulatory Pathway: The pace at which FDA and EMA may review lanifibranor for Breakthrough Therapy designation.
Competitive Positioning: How Inventiva’s pan-PPAR approach differentiates it from other MASH therapies in development.